Pfizer PFE Tukysa — Indefinite-lived intangible assets, period increase (decrease)

Other product segments

Similar metrics at other companies

BIIBTysabri Product — Finite Lived Intangible Assets Net

$1.8B-9.1%

UTHRTrevyent — Indefinite-lived intangible assets (excluding goodwill)

$107.3M—

UTHRTrevyent — Intangible asset impairment charges

$107.3M—

JNJMedTech — Indefinite-lived trademarks

$1.7B—

BIIBVUMERITY — Finite Lived Intangible Assets Period Increase Decrease

$155M—

ALife Sciences and Applied Markets — Additions and adjustments to other intangibles

$186M—

Questions, answered.

What is Pfizer's tukysa — indefinite-lived intangible assets, period increase (decrease)?

Pfizer (PFE) reported tukysa — indefinite-lived intangible assets, period increase (decrease) of -$580M in Q1 2026.

What does tukysa — indefinite-lived intangible assets, period increase (decrease) mean?

The net change in the value of non-amortizing intangible assets linked to the Tukysa product line.

How do you interpret tukysa — indefinite-lived intangible assets, period increase (decrease)?

An increase typically reflects strategic investment or acquisition of rights, while a decrease often signals impairment charges or asset write-downs.

How does tukysa — indefinite-lived intangible assets, period increase (decrease) compare across companies?

Comparable to IPR&D or brand asset adjustments reported by other pharmaceutical companies following M&A activity.